Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bladder Wall Perfusion Pattern and Sexual Dysfunction in Female Patients With Lower Urinary Tract Symptoms, and the Association of That Perfusion Pattern and Therapeutic Efficacy of Antimuscarinics for Female Overactive Bladder Syndrome

Next Previous
Search
Trial Profile

Bladder Wall Perfusion Pattern and Sexual Dysfunction in Female Patients With Lower Urinary Tract Symptoms, and the Association of That Perfusion Pattern and Therapeutic Efficacy of Antimuscarinics for Female Overactive Bladder Syndrome

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 May 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tolterodine (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use

    • Most Recent Events

    • 11 Jan 2019 Status changed from recruiting to completed.
    • 04 Sep 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 04 Sep 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jul 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top